Healthcare & Pharmaceuticals Blog
As Seen In
Cybersecurity incidents and data compromises continue to plague financial institutions on a seemingly daily basis. Without a proper response plan in place, financial institutions risk significant damage to their reputation and operations >
Services
Region
Industries
- Agriculture
- Corporate & Business
- Crossborder Trade & Investment
- Dispute Resolution
- Employment & Labor
- Energy & Natural Resources
- Environmental
- Financial Services
- Government & Public Sector
- Healthcare & Pharmaceuticals
- Hospitality, Media & Leisure
- Industrial & Manufacturing
- Insurance
- Life Sciences
- Real Estate & Construction
- Retail & Distribution
- Taxation
- Technology
- Telecommunications
- Transportation
Recent Posts
- Blog: Haynes and Boone BlogsIRS Announces Proposed Regulations Implementing New Hardship Distribution RequirementsPosted on November 16, 2018 by Haynes and Boone Benefits GroupThe IRS recently published proposed regulations addressing changes enacted by the Tax Cuts and Jobs Act of 2017, the Bipartisan Budget Act of 2018, and other prior changes to the tax code. Specifically, the proposed regulations: Permit, but don’t require, hardship distributions from a participant’s elective contributions, QNECs, QMACs (including safe harbor matching contributions), and […] The post IRS Announces Proposed Regulations Implementing New Hardship Distribution Requirements appeared first on Haynes and Boone Blogs.
- Blog: Biologics BlogBill Requiring Disclosure of Biosimilar Settlement Agreements to the FTC and DOJ Becomes LawPosted on October 28, 2018 by Earlier this month, the President signed into law the Patient Right to Know Drug Prices Act (Public Law 115-263). The Act mainly focuses on eliminating so-called “gag clauses” that prevent pharmacists from telling patients when paying for a drug out of pocket is cheaper than paying through insurance. In addition, the Act amends the Medicare [...]
- Blog: EndpointsFormer FDA Counsel Joins Verrill Dana’s Health Care GroupPosted on July 16, 2018 by Academic and Clinical Research GroupWe are pleased to welcome attorney Katlin McKelvie Backfield to our nationally recognized Health Care Group. Katlin comes to Verrill Dana with more than 15 years of pharmaceutical regulatory experience, including more than a decade at the Food and Drug Administration. While at the FDA, Katlin served as Associate Chief Counsel for Drugs in the Office of Chief Counsel and as a Regulatory Counsel in the Division of Drug Marketing, Advertising, and Communications (DDMAC) (now the Office of Prescription Drug Promotion). Prior to joining [...]
